Clark WL - Search Results

1

Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.

Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Wykoff CC, et al. Among authors: clark wl. J Manag Care Spec Pharm. 2018 Feb;24(2-a Suppl):S3-S15. doi: 10.18553/jmcp.2018.24.2-a.s3. J Manag Care Spec Pharm. 2018. PMID: 29383980 Review.

2

Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA. Heier JS, et al. Among authors: clark wl. Ophthalmology. 2014 Jul;121(7):1414-1420.e1. doi: 10.1016/j.ophtha.2014.01.027. Epub 2014 Mar 27. Ophthalmology. 2014. PMID: 24679444 Clinical Trial.

3

Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.

Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, Wang R, Clark WL, Boyer DS; ENDURANCE Study Group. Wykoff CC, et al. Among authors: clark wl. Am J Ophthalmol. 2017 Jan;173:56-63. doi: 10.1016/j.ajo.2016.09.029. Epub 2016 Oct 1. Am J Ophthalmol. 2017. PMID: 27702624 Clinical Trial.

4

Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.

Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM, Clark WL, Abdelfattah NS, Sadda SR; TREX-AMD Study Group. Wykoff CC, et al. Among authors: clark wl. Br J Ophthalmol. 2018 Apr;102(4):460-464. doi: 10.1136/bjophthalmol-2017-310822. Epub 2017 Aug 4. Br J Ophthalmol. 2018. PMID: 28779006 Clinical Trial.

5

Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study.

Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, Clark WL, Abdelfattah NS, Sadda SR; TREX-AMD Study Group. Wykoff CC, et al. Among authors: clark wl. Ophthalmol Retina. 2017 Jul-Aug;1(4):314-321. doi: 10.1016/j.oret.2016.12.004. Epub 2017 Feb 2. Ophthalmol Retina. 2017. PMID: 31047517

6

Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.

Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Payne JF, et al. Among authors: clark wl. Br J Ophthalmol. 2021 Feb;105(2):253-257. doi: 10.1136/bjophthalmol-2020-316176. Epub 2020 Apr 17. Br J Ophthalmol. 2021. PMID: 32303499 Clinical Trial.

7

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.

Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Brown DM, et al. Among authors: clark wl. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955. doi: 10.1001/jamaophthalmol.2021.2809. JAMA Ophthalmol. 2021. PMID: 34351414 Free PMC article. Clinical Trial.

8

Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.

Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA. Brown DM, et al. Among authors: clark wl. Am J Ophthalmol. 2013 Mar;155(3):429-437.e7. doi: 10.1016/j.ajo.2012.09.026. Epub 2012 Dec 4. Am J Ophthalmol. 2013. PMID: 23218699 Clinical Trial.

9

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA. Clark WL, et al. Ophthalmology. 2016 Feb;123(2):330-336. doi: 10.1016/j.ophtha.2015.09.035. Epub 2015 Oct 30. Ophthalmology. 2016. PMID: 26522708 Clinical Trial.

10

Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema.

Clark WL, Boyer DS, Kaiser PK. Clark WL, et al. JAMA Ophthalmol. 2017 Mar 1;135(3):291. doi: 10.1001/jamaophthalmol.2016.5676. JAMA Ophthalmol. 2017. PMID: 28152149 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results